Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Csl Behring Gmbh

Home Clinical Trial Sponsors and OrganizationsCsl Behring Gmbh

Csl Behring Gmbh

ACTIVE

Germanywww.cslbehring.deSubsidiary

Part of CSL Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

177

166 active

Approvals

94

Total approvals

Agencies

6

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

88

49.7%

Phase 3

7

4.0%

Phase 2

1

0.6%

Trial Status Distribution

Active, not recruiting

166

93.8%

Completed

9

5.1%

Recruiting

2

1.1%

Clinical Trials

Trials sponsored by this organization (177)

Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in Chinese subjects with hemophilia B previously treated with FIX therapy

Active, not recruiting

Acquired FXIII Deficiency: Real World Evidence on Laboratory Diagnosis and presentation of FXIII supplementatio

Dec 2022200 participants

CSL964_5003: Benefits of patient self-administration and Respreeza® 4g and 5g vials - an observational study

Dec 202217 participants

Study to Investigate CSL112 in Subjects with Acute Coronary Syndrome

Active, not recruiting

Jun 202117,400 participants

ong-term safety and efficacy of CSL312 (garadacimab) in the prophylactictreatment of hereditary angioedema attacks

Active, not recruiting

Jun 2021150 participants

CSL312 (garadacimab) in the prevention of hereditary angioedema attacks

Active, not recruiting

Jun 202160 participants

Efficacy and Safety of IgPro10 in Adults with Systemic Sclerosis (SSc)

Active, not recruiting

Jan 2021144 participants

A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM)

Active, not recruiting

Jan 2021126 participants

Page 1 of 23

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

3

Approvals

FDA

Food and Drug Administration

1

Approvals

EMA

European Medicines Agency

13

Approvals

PHILIPPINES

Philippines FDA

3

Approvals

NPRA

National Pharmaceutical Regulatory Agency

17

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

57

Approvals

Recent Approvals

HIZENTRA 200 MG/ML SOLUCION INYECTABLE SUBCUTANEA EN JERINGA PRECARGADA

IDELVION 2000 IU powder and solvent for solution for injection

Haemocomplettan P 1g Powder for solution for injection / infusion

IDELVION 250 IU powder and solvent for solution for injection

AFSTYLA 1000IU powder and solvent for solution for injection

AFSTYLA 500IU powder and solvent for solution for injection

Beriate 250 IU Powder and solvent for solution for injection or infusion

Haemate P 1000IU Powder and solvent for solution for injection or infusion

AFSTYLA 250IU powder and solvent for solution for injection

News

No news articles found

On this page

Overview
Clinical Trials177
Approvals94
News

Back to Organizations